Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Cancer vaccine heat shock protein peptide complex-96 - Agenus; Cancer vaccine HSPPC-96; G-100; G-200; Heat shock protein peptide complex 96 cancer vaccine - Agenus; Heat-shock protein-based vaccine; HSPPC-96; NP-150; Oncophage; Prophage series G-100 vaccine; Prophage series G-200 vaccine; Prophage™ heat shock protein-based autologous vaccine

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fordham University; Mount Sinai School of Medicine
  • Developer Agenus; University of Texas Health Science Center at Houston
  • Class Antineoplastics; Cancer vaccines; Heat shock proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Malignant melanoma; Renal cell carcinoma
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Marketed Renal cell carcinoma
  • Phase II Glioma; Malignant melanoma
  • No development reported Brain cancer; Colorectal cancer; Gastric cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Pancreatic cancer
  • Discontinued Chronic myeloid leukaemia; Leukaemia; Sarcoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Brain-cancer(In children, In infants) in USA (Intradermal)
  • 17 Jan 2017 Agenus and National Cancer Institute plan a phase II trial of vitespen and pembrolizumab for Glioma (Combination therapy, Newly diagnosed) in USA
  • 08 Feb 2016 The University of Texas Health Science Center and Agenus withdraw a phase I/II trial for Malignant melanoma (Combination therapy, Late-stage disease) in USA (NCT02452281)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top